Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$15.60 0.10 (0.65%)
2/9/2010 4:00 PM

InterMune, Inc. (ITMN)

CAPS Rating:
**

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ITMN

Add Stock to Watchlist

What the Community Thinks

Total Members

145 Outperforms
45 Underperforms
 

All-Stars

48 Outperforms
22 Underperforms
 

Wall Street

11 Outperforms
2 Underperforms
 

Members bullish on ITMN are also bullish on:

Members bearish on ITMN are also bearish on:

Ticker Tags

Defensive (1457), Biotechnology (220), Small Cap (1645), Spin-off - 2006 (19), Healthcare (711)
Suggest a tag

InterMune, Inc. At A Glance

Current Price: $15.60
Last Trade Time: 2/9/2010 4:00 PM
Open: $0.00
Previous Close: $15.50
Daily Range: $15.50 - $16.05
52-Week Range: $10.48 - $19.12
Volume: 850,026
Market Cap: $728.04M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

ITMN VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

InterMune, Inc. (ITMN)

Avatar lanoush (66.34) Submitted: 1/12/07 1:16 PM

ITMN's hep C product has a chance to become a standard treatment, alongside VRTX's product. Recently a quick test for Hep C was introduced and is being marketed to doctors. It could make it more common for Hep C testing to become a standard screen, since many who have it don't become symptomatic for...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

InterMune, Inc. (ITMN)

Avatar asabah (90.99) Submitted: 6/27/07 10:25 PM

Finding a single compound as an inhibitor of Hepititis C virus (HCV) is not an easy task. HCV has 6 different genotypes and within each genotype there are a number of subtypes. It is an RNA virus which mutates very quickly. Therefore in a single infected individual there are a number of quisiespecie...More

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 23 :   1 2 3 4 5 Next »

Recs

0

 (ITMN)

Avatar Biotech2010 (40.47) Submitted: 1/26/10 8:56 PM : Underperform Start Price: $14.13 ITMN Score: -12.19

13.47

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ITMN)

Avatar zzlangerhans (99.64) Submitted: 1/11/10 6:55 PM : Underperform Start Price: $14.89 ITMN Score: -10.69

The pirfenidone NDA has been submitted and accepted by the FDA for priority review, with a PDUFA of May 4, 2010. The share price has been propelled upward by these rather predictable events as well as ongoing mildly encouraging data for the hep C candidate RG7227 (formerly ITMN-191). Pirfenidone will receive a Complete Response letter either on May 4 as scheduled, or some time in the late summer after a PDUFA delay and advisory panel meeting. The Complete Response letter will request a new phase III trial. The share price will tank below 10.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ITMN)

Avatar bvdbreaker (< 20) Submitted: 10/08/09 7:42 AM : Outperform Start Price: $14.06 ITMN Score: 10.32

undervalued pipeline, period

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ITMN)

Avatar TMFBiologyFool (95.94) Submitted: 8/06/09 3:52 PM : Underperform Start Price: $14.89 ITMN Score: 1.96

Won't get a decision from the FDA until the middle of next year.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ITMN)

Avatar pmtrain (98.28) Submitted: 2/10/09 5:26 AM : Outperform Start Price: $18.62 ITMN Score: -42.68

hpc trials are taking this company higher almost daily feb 2009 (best owned performer)

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 23 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 13 of 13  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackWedbush 66.12 10/21/09 Outperform NS $13.41+16.33%-1.67%+18.00
TrackThinkEquity 64.82 09/21/09 Underperform NS $16.06-2.86%+1.26%+4.12
TrackMerriman < 20 08/12/09 Outperform NS $14.45+7.96%+8.21%-0.25
TrackWallStreetA 80.18 12/11/08 Outperform NS $12.93+20.65%+21.89%-1.24
TrackOppenheimer 81.36 12/01/08 Outperform NS $11.30+38.05%+25.71%+12.35
TrackCanaccord 86.15 02/12/08 Outperform NS $15.71-0.70%-17.33%+16.63
TrackJPMorgan 84.76 09/27/07 Outperform NS $20.00-22.00%-26.54%+4.54
TrackLazardCapit < 20 09/19/07 Outperform NS $19.96-21.84%-26.58%+4.73
TrackBofASec 94.61 04/24/07 Outperform NS $29.90-47.83%-23.53%-24.29
TrackJMP 71.98 01/04/07 Outperform NS $30.12-48.21%-19.42%-28.79
TrackSusquehanna 74.67 11/21/06 Outperform NS $22.04-29.22%-19.00%-10.22
TrackDeutscheSec 89.68 10/17/06 Outperform NS $21.99-29.06%-16.53%-12.53
TrackJimCramer < 20 10/17/06 Underperform 3W $21.12-26.14%-16.42%+9.72

Results 1 - 13 of 13  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD03 656ms